| Literature DB >> 35495152 |
Zongliang Yue1, Radomir Slominski1,2, Samuel Bharti1, Jake Y Chen1.
Abstract
Functional genomics studies have helped researchers annotate differentially expressed gene lists, extract gene expression signatures, and identify biological pathways from omics profiling experiments conducted on biological samples. The current geneset, network, and pathway analysis (GNPA) web servers, e.g., DAVID, EnrichR, WebGestaltR, or PAGER, do not allow automated integrative functional genomic downstream analysis. In this study, we developed a new web-based interactive application, "PAGER Web APP", which supports online R scripting of integrative GNPA. In a case study of melanoma drug resistance, we showed that the new PAGER Web APP enabled us to discover highly relevant pathways and network modules, leading to novel biological insights. We also compared PAGER Web APP's pathway analysis results retrieved among PAGER, EnrichR, and WebGestaltR to show its advantages in integrative GNPA. The interactive online web APP is publicly accessible from the link, https://aimed-lab.shinyapps.io/PAGERwebapp/.Entities:
Keywords: GNPA; PAGER; PAGER Web APP; functional genomics; geneset analysis; melanoma; network visualization and analysis
Year: 2022 PMID: 35495152 PMCID: PMC9039620 DOI: 10.3389/fgene.2022.820361
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.772
FIGURE 1The PAGER Web APP data analysis workflow. The workflow consists of four steps with visualization panels to help biologists quickly understand the results.
A comparison of data coverage and features among PAGER, EnrichR, and WebGestalt web servers.
| Webserver | PAGER | EnrichR | Webgestalt | |
|---|---|---|---|---|
| Data coverage (Human) | Unique library | 35 | 89 | 22 |
| Metadata | Yes | Partial | Partial | |
| Gene prioritization | Yes | No | No | |
| Geneset intra-network | Interactions | Yes | No | Partial |
| Regulations | Yes | No | Partial | |
| Geneset inter-network | m-type (co-membership) | Yes | Partial | Partial |
| r-type (regulatory) | Yes | No | No | |
| Additional feature | Term searching | Yes | Yes | No |
| API | Yes | Yes | Yes | |
FIGURE 2The enriched pathway results for melanoma drug resistant-sensitive patients. (A) The consensus pathways among PAGER, EnrichR and WebGestaltR results. (B) The composition of P-type PAGs enriched in PAGER. (C) The top-30 enriched P-type PAGs are ordered by FDR in PAGER.
FIGURE 3The m-type PAG-to-PAG network of enriched P-type PAGs in PAGER for melanoma drug resistant-sensitive patients. (A) The m-type PAG-to-PAG network overview and (B) The extracted word clouds from the Louvain clusters in the network.
The 33 consensus pathways among PAGER, EnrichR, and WebGestaltR results with PubMed literature support. W vs. P represents the term similarities between WebGestaltR and PAGER results. P vs. E represents the term similarities between PAGER and EnrichR results. W vs. E represents the term similarities between WebGestaltR and EnrichR. represents the citations of “melanoma” and the keywords from a pathway. represents the odds ratio. Score represents the . PMID represents one PubMed ID example from each entry. BEERE validation represents the semantic relationships retrieved. 1 stands for Yes, and 0 stands for No. All these abbreviations are applied to Table 3 and Table 4.
| Term | W vs. P (%) | P vs. E (%) | W vs. E (%) | Keywords | k | OR | Score | PMID | BEERE validation |
|---|---|---|---|---|---|---|---|---|---|
| Photodynamic therapy-induced ap-1 survival signaling. | 100 | 100 | 100 | Photodynamic therapy | 1,076 | 1.150 | 1.20E+01 | 31378787 | 1 |
| mir-509-3p alteration of yap1/ecm axis | 100 | 100 | 100 | mir-509-3p | 3 | 2.376 | 1.94E+00 | 33968718 | 1 |
| Transcriptional misregulation in cancer | 100 | 100 | 100 | Transcriptional misregulation in cancer | 10 | 1.261 | 1.27E+00 | 32079144 | 1 |
| Photodynamic therapy-induced nf-kb survival signaling | 100 | 100 | 100 | Photodynamic, nf-kb | 2 | 1.261 | 7.40E-01 | 16524427 | 1 |
| Apoptosis-related network due to altered notch3 in ovarian cancer | 100 | 100 | 100 | Notch3 ovarian cancer | 2 | 1.154 | 6.49E-01 | 28165469 | 1 |
| Senescence and autophagy in cancer | 100 | 100 | 100 | Senescence and autophagy in cancer | 35 | 0.722 | 1.97E-02 | 12789281 | 1 |
| Focal adhesion: pi3k-akt-mtor-signaling pathway | 96 | 96 | 100 | pi3k-akt-mtor-signaling pathway | 36 | 0.699 | 1.04E-02 | 31370278 | 0 |
| Cytokine-cytokine receptor interaction | 100 | 100 | 100 | Cytokine-cytokine receptor | 14 | 0.442 | 1.72E-04 | 34824546 | 1 |
| il-18 signaling pathway | 100 | 100 | 100 | il-18 pathway | 25 | 0.482 | 1.54E-05 | 31731729 | 1 |
| Mirna targets in ecm and membrane receptors | 100 | 100 | 100 | mirna membrane receptors | 2 | 0.104 | 1.22E-07 | 34680340 | 0 |
| c-type lectin receptor signaling pathway | 100 | 100 | 100 | c-type lectin receptor signaling pathway | 28 | 0.360 | 4.03E-11 | 29497419 | 1 |
| Nod-like receptor signaling pathway | 100 | 100 | 100 | Nod-like receptor signaling pathway | 50 | 0.394 | 5.13E-15 | 34747716 | 0 |
| il-17 signaling pathway | 100 | 100 | 100 | il-17 pathway | 20 | 0.215 | 2.80E-20 | 30079767 | 1 |
| Protein digestion and absorption | 100 | 100 | 100 | Protein digestion and absorption | 5 | 0.062 | 4.10E-29 | 30900145 | 0 |
| Assembly of collagen fibrils and other multimeric structures | 100 | 100 | 100 | Collagen assembly | 13 | 0.126 | 2.30E-29 | 29216889 | 1 |
| Bladder cancer | 100 | 100 | 100 | Bladder cancer | 1815 | 0.708 | 6.34E-53 | 35059301 | 1 |
| Class a/1 (rhodopsin-like receptors) | 100 | 100 | 100 | Adenosine a1 receptor | 10 | 0.056 | 8.79E-63 | 8463264 | 1 |
| Legionellosis | 100 | 100 | 100 | Legionellosis | 1 | 0.006 | 7.10E-77 | 17870669 | 0 |
| Prostaglandin synthesis and regulation | 100 | 100 | 100 | Prostaglandin synthesis and regulation | 75 | 0.162 | 5.42E-110 | 3149408 | 1 |
| Response to elevated platelet cytosolic ca2+ | 100 | 100 | 100 | Platelet, calcium | 44 | 0.105 | 1.95E-120 | 32562975 | 1 |
| Hepatitis c and hepatocellular carcinoma | 100 | 100 | 100 | Hepatitis c and hepatocellular carcinoma | 20 | 0.054 | 4.73E-127 | 31538700 | 0 |
| Interleukin-6 family signaling | 100 | 100 | 100 | il-6 signaling pathway | 170 | 0.237 | 2.42E-131 | 22713796 | 1 |
| tnf signaling pathway | 100 | 100 | 100 | tnf signaling pathway | 246 | 0.260 | 1.65E-159 | 30591049 | 1 |
| Inflammatory response pathway | 100 | 100 | 100 | Inflammatory response pathway | 123 | 0.173 | 2.30E-161 | 32517213 | 1 |
| Amoebiasis | 100 | 100 | 100 | Amoebiasis | 5 | 0.012 | 2.14E-177 | 31173190 | 0 |
| Pertussis | 100 | 100 | 100 | Pertussis | 83 | 0.083 | 1.46E-303 | 23737697 | 1 |
| Cytokines and inflammatory response | 100 | 100 | 100 | Cytokines, inflammatory response | 559 | 0.212 | 0.00E+00 | 31176707 | 0 |
| Lung fibrosis | 100 | 100 | 100 | Lung fibrosis | 118 | 0.057 | 0.00E+00 | 31249780 | 1 |
| Malaria | 100 | 100 | 100 | Malaria | 137 | 0.044 | 0.00E+00 | 14657217 | 1 |
| Micrornas in cancer | 100 | 100 | 100 | Micrornas | 1,211 | 0.342 | 0.00E+00 | 28118616 | 1 |
| Rheumatoid arthritis | 100 | 100 | 100 | Rheumatoid arthritis | 357 | 0.074 | 0.00E+00 | 27307502 | 0 |
|
| 100 | 100 | 100 |
| 168 | 0.057 | 0.00E+00 | 11773163 | 0 |
| Spinal cord injury | 100 | 100 | 100 | Spinal cord injury | 82 | 0.034 | 0.00E+00 | 30008656 | 0 |
The 23 consensus pathways between PAGER, EnrichR results with PubMed literature support.
| Term | P vs. E (%) | Keywords | k | OR | Score | PMID | BEERE validation |
|---|---|---|---|---|---|---|---|
| axl signaling pathway | 86 | axl signaling | 45 | 1.533 | 5.30E+00 | 31871265 | 0 |
| g alpha (i) signaling events | 97 | g protein alpha signaling events | 15 | 0.699 | 6.33E-02 | 33588787 | 1 |
| Vitamin d receptor pathway | 100 | Vitamin d receptor pathway | 23 | 0.734 | 5.49E-02 | 28218743 | 0 |
| Age-rage signaling pathway in diabetic complications | 100 | Age-rage signaling pathway, diabetes | 1 | 0.200 | 7.12E-03 | 25909054 | 0 |
| Activation of nlrp3 inflammasome by sars-cov-2 | 100 | Viral protein interaction, cytokine receptor | 154 | 0.580 | 8.48E-14 | 26920710 | 0 |
| Viral protein interaction with cytokine and cytokine receptor | 100 | nlrp3 inflammasome | 14 | 0.225 | 6.84E-14 | 33649199 | 1 |
| pi3k-akt signaling pathway | 100 | pi3k-akt signaling pathway | 475 | 0.693 | 2.33E-17 | 22453015 | 0 |
| Jak-stat signaling pathway | 100 | Jak-stat signaling pathway | 103 | 0.478 | 1.39E-17 | 32194688 | 0 |
| Kaposi sarcoma-associated herpesvirus infection | 100 | Kaposi sarcoma-associated herpesvirus infection | 12 | 0.085 | 2.15E-45 | 16443048 | 0 |
| Proteoglycans in cancer | 100 | Proteoglycans | 766 | 0.554 | 8.83E-72 | 31140988 | 0 |
| Hematopoietic cell lineage | 100 | Hematopoietic cell lineage | 63 | 0.130 | 3.82E-128 | 26391013 | 0 |
| Adipogenesis | 100 | Adipogenesis | 25 | 0.060 | 1.48E-139 | 27216185 | 0 |
| nf-kappa b signaling pathway | 100 | nf-kappa b signaling | 432 | 0.341 | 1.46E-158 | 22433222 | 1 |
| Glucocorticoid receptor pathway | 100 | Glucocorticoid receptor | 131 | 0.168 | 1.91E-179 | 31911848 | 1 |
| Gastrin signaling pathway | 100 | Gastrin | 23 | 0.034 | 3.80E-246 | 1,6242076 | 1 |
| Allograft rejection | 100 | Allograft rejection | 76 | 0.081 | 2.85E-288 | 26951628 | 0 |
| Human papillomavirus infection | 100 | Papillomavirus | 405 | 0.237 | 6.17E-308 | 10767787 | 1 |
| Selenium micronutrient network | 100 | Selenium | 129 | 0.112 | 2.82e-318 | 23470450 | 1 |
| Nanomaterial-induced inflammasome activation | 100 | Nanotechnology | 563 | 0.160 | 0.00E+00 | 28303522 | 0 |
| Covid-19 adverse outcome pathway | 100 | Covid-19 | 289 | 0.043 | 0.00E+00 | 32734626 | 0 |
| Pathogenic | 100 |
| 431 | 0.033 | 0.00E+00 | 34912719 | 0 |
| Lipid and atherosclerosis | 100 | Lipid, atherosclerosis | 21 | 0.012 | 0.00E+00 | 29903879 | 1 |
| Human cytomegalovirus infection | 100 | Cytomegalovirus | 195 | 0.125 | 0.00E+00 | 15922119 | 1 |
The 5 consensus pathways between PAGER, WebGestaltR results with PubMed literature support.
| Term | W vs. P (%) | Keywords | k | OR | Score | PMID | BEERE validation |
|---|---|---|---|---|---|---|---|
| Binding and uptake of ligands by scavenger receptors | 100 | Ligands, scavenger receptors | 12 | 0.398 | 6.77E-05 | 31244937 | 0 |
| Interleukin-4 and interleukin-13 signaling | 100 | Interleukin-4, interleukin-13 | 9 | 0.114 | 5.68E-24 | 23972995 | 1 |
| Collagen chain trimerization | 100 | Collagen chain | 153 | 0.257 | 4.14E-102 | 21853302 | 0 |
| Interleukin-10 signaling | 100 | Interleukin-10 | 349 | 0.332 | 1.05E-136 | 7852279 | 1 |
| Post-translational protein phosphorylation | 100 | Protein phosphorylation | 2,850 | 0.301 | 0 | 17973544 | 0 |
FIGURE 4The top-ranked enriched pathways using the PubMed score and the expression of those overlapped genes with gene regulatory networks for melanoma drug resistant-sensitive patients. In the box plots, the x-axis are the overlapped genes between differentially expressed gene candidates and pathway gene members, and the y-axis are the gene expression values. In the gene regulatory networks, a red arrow indicates the direction of activation, and a green arrow indicates the direction of inhibition. WAG002532 and WAG002805 are the PAG IDs of the enriched pathways shown in (A) The pathway with the highest PubMed score in Table 2, and (B) one of the PubMed literature validated pathways in Table 3. The details of pathways shown can be retrieved online from: http://discovery.informatics.uab.edu/PAGER/index.php/geneset/view/[PAG ID].
The performance of the three tools. represents the citations of “melanoma” and the keywords from a pathway. represents the odds ratio. represents the .
| Tool | Precision | ||
|---|---|---|---|
|
| OR > 0.1 | score > 10e-5 | |
| PAGER | 0.95 | 0.75 | 0.30 |
| EnrichR | 0.89 | 0.65 | 0.29 |
| WebGestalt | 0.99 | 0.70 | 0.24 |
FIGURE 5The performance comparisons among PAGER, EnrichrR and WebGestaltR using Receiver Operator Characteristic (ROC) curve and the t-test curve. The pathways’ adjusted p-values were applied to generate the ROC curves. The PubMed scores were used for the t-test curve. (A) The sclerosis study (E-GEOD-21942). (B) The inflamed colonic mucosa vs. non-inflamed colonic mucosa in Crohn’s disease study. (C) The inflamed colonic mucosa vs. non-inflamed colonic mucosa in the ulcerative colitis study.